Research Topics
Species | David NanusSummaryAffiliation: Cornell University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigenDavid M Nanus
Department of Medicine, Joan and Stanford I Weill Medical College of Cornell University, New York, NY 10021, USA
J Urol 170:S84-8; discussion S88-9. 2003..Monoclonal antibody (mAb) J591 recognizes the extracellular domain of PSMA. The current status of clinical trials using mAb J591 is reviewed...- Interaction of retinoic acid and interferon in renal cancer cell linesD M Nanus
Department of Urology, Joan and Sanford I Weill Medical College of Cornell University, New York, NY 10021, USA
J Interferon Cytokine Res 20:787-94. 2000..IFN-gamma pretreatment enhanced the upregulation of p48 levels by IFN-alpha. Combining RA and IFN results in additive growth inhibition on RCC cell lines. This increase in growth inhibition is not mediated by increased ISGF3 expression... - Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinomaDavid M Nanus
Department of Medicine, Weill Medical College of Cornell University, New York, New York, USA
Cancer 101:1545-51. 2004..Based on the antitumor activity of doxorubicin and gemcitabine in collecting duct carcinoma of the kidney, the authors used this combination to treat selected patients with sarcomatoid or rapidly progressing RCC... - Advanced renal cell carcinomaM I Milowsky
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, 525 East 68th Street, B-1519, New York, NY 10021, USA
Curr Treat Options Oncol 2:437-45. 2001..The identification of new agents with more effective antitumor activity is a high priority in the treatment of advanced RCC... - Reduced levels of retinyl esters and vitamin A in human renal cancersX Guo
Department of Pharmacology, Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer Res 61:2774-81. 2001.... - New treatment approaches for metastatic renal cell carcinomaD M Nanus
Division of Hematology and Medical Oncology, Departments of Medicine and Urology, Joan and Sanford I Weill Medical College of Cornell University, 525 East 68th Street, B 1519, New York, NY 10021, USA
Curr Oncol Rep 2:417-22. 2000..A number of novel treatment strategies are being investigated with some encouraging early results. The identification of new agents with better antitumor activity remains a high priority in the treatment of advanced renal cell carcinoma... - Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoproteinD M Nanus
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021
Cancer Res 50:4190-4. 1990..We conclude that the absence of gp160 expression by RCs may be predictive of sensitivity to the antitumor effects of IFN-alpha and, thus, provide a basis for identifying IFN-responsive patients... 
Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatmentTrisha S Tavares
Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, NY 10065, USA
Cancer Biol Ther 7:1607-18. 2008..Together, our results show that treatment of RCC with cRA and/or SAHA increases the expression of several genes and gene families that result in reduced cell proliferation...- Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase AD M Nanus
Laboratory of Mammalian Cell Transformation, Memorial Sloan Kettering Cancer Center, New York, NY 10021
Proc Natl Acad Sci U S A 90:7069-73. 1993..These data indicate that the gp160 human kidney/RCC glycoprotein is human APA... - Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approachAshutosh Tewari
Brady Urologic Health Center, New York Presbyterian Hospital and Robotic Prostatectomy and Urologic Oncology Outcomes, Weill Medical College of Cornell University, New York, New York 10021, USA
J Urol 177:911-5. 2007.... - Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cellsJ Dai
Department of Urology, Urological Oncology Research Laboratory, Joan and Stanford I. Weill Medical College of Cornell University, New York, New York 10021, USA
Clin Cancer Res 7:1370-7. 2001..These data show that NEP can inhibit PC cell growth and tumorigenicity and suggest that NEP has potential as therapy for androgen-independent PC... - Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathwayM Sumitomo
Urologic Oncology Research Laboratory, Department of Urology, Weill Medical College of Cornell University, New York, NY 10021, USA
Cancer Res 61:3294-8. 2001..These data show that the neuropeptides ET-1 and bombesin stimulate ligand-independent activation of the IGF-IR, which results in Akt activation, and that this cross-communication between GPCR and IGF-IR signaling is inhibited by NEP... - Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signalingM Sumitomo
Urologic Oncology Research Laboratory, Department of Urology, and Department of Pathology, Weill Medical College of Cornell University, New York, New York, USA
J Clin Invest 106:1399-407. 2000.... - Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancerB A Usmani
Genitourinary Oncology Research Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Br J Cancer 82:550-2. 2000..The observed frequencies in patients who develop renal cancer was not significantly different than the normal population... - Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinomaStephen A Boorjian
Department of Urology, the Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, New York, NY 10021, USA
J Immunother 30:655-62. 2007..The addition of weekly ATRA-IV to IFN therapy is feasible and well tolerated, resulting in sustainable increased serum (RA). This regimen demonstrates antitumor activity in metastatic RCC, and suggests ATRA-IV augments IFN therapy... - Neutral endopeptidase protein expression and prognosis in localized prostate cancerIman Osman
Department of Urology, New York University Cancer Institute, Kaplan Comprehensive Cancer Center, New York, New York, USA
Clin Cancer Res 10:4096-100. 2004..We investigated whether decreased NEP expression in localized prostate cancers is associated with prostate-specific antigen (PSA) relapse after radical prostatectomy... - Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?Shankar Vallabhajosula
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, New York, USA
J Nucl Med 46:634-41. 2005..The radiation dosimetry of 90Y-J591 was estimated based on both 111In and 177Lu data to validate the usage of 111In as a chemical and biologic surrogate for 90Y... - Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancerNeil H Bander
Department of Urology, Weill Medical College of Cornell University, 525 E 68th St, E 300, New York, NY 10021, USA
J Clin Oncol 23:4591-601. 2005.... - Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor modelSue Ellen Touma
Department of Pharmacology, Weill Medical College of Cornell University, New York, New York 10021, USA
Clin Cancer Res 11:3558-66. 2005..These results indicate that ATRA and histone deacetylase inhibitor therapies should be explored for the treatment of advanced RCC... - Involvement of neutral endopeptidase in neoplastic progressionMakoto Sumitomo
Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
Biochim Biophys Acta 1751:52-9. 2005..We review the mechanisms of NEP's tumor suppressive action and how NEP loss contributes to tumor progression... - Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicityShankar Vallabhajosula
Department of Radiology, Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York 10021, USA
Clin Cancer Res 11:7195s-7200s. 2005..Fractionated dose regimens may decrease myelotoxicity and increase greater total administered dose. We have studied the effect of two or three treatments of 177Lu-J591 and 90Y-J591 monoclonal antibodies (mAb) on myelotoxicity... - Clinical utility of radiolabeled monoclonal antibodies in prostate cancerKevin A David
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
Clin Genitourin Cancer 4:249-56. 2006..Additional studies are under way to better define the activity of radiolabeled antibody therapy as well as the role for fractionated therapy and combination approaches with taxane-based chemotherapy... - Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2Oscar B Goodman
Urologic Oncology Research Laboratory, Department of Urology, Weil Medical College of Cornell University New York Presbyterian Hospital, New York, NY 10021, USA
J Biol Chem 281:33597-605. 2006..These data indicate that neprilysin proteolytically inactivates fibroblast growth factor-2, resulting in negative regulation of angiogenesis... - Chemotherapy for non-clear-cell renal cell carcinomaKevin A David
Department of Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital, NY 10021, USA
Clin Genitourin Cancer 4:263-8. 2006..In this article, we will review the literature and present our experience with the use of chemotherapy in patients with non-clear-cell kidney cancer by histologic subtype... - Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progressionIman Osman
Department of Urology, New York University Cancer Institute, New York, New York, USA
Cancer 107:2628-36. 2006.... - Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumorsMatthew I Milowsky
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York 10021, USA
J Clin Oncol 25:540-7. 2007..This was a proof-of-principle evaluation of PSMA as a potential neovascular target. The primary end points were targeting,toxicity, maximum-tolerated dose, pharmacokinetics (PK), and human antihuman antibody (HAHA) response... - Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancerStephen Boorjian
Department of Urology, New York Presbyterian Hospital Weill Cornell Medical Center, New York, New York 10021, USA
Clin Cancer Res 10:3429-37. 2004..Here we evaluated expression of LRAT protein and mRNA in normal and malignant bladder tissue specimens from human patients. We also examined the effect of retinoids on LRAT expression in bladder cancer cell lines... - Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trialMaha H A Hussain
University of Michigan, Ann Arbor, USA
J Clin Oncol 25:2218-24. 2007.... - Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancerMatthew I Milowsky
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
J Clin Oncol 22:2522-31. 2004..5 mCi/m(2). Acceptable toxicity, excellent targeting of known sites of PC metastases, and biologic activity in patients with androgen-independent PC warrant further investigation of (90)Y-J591 in the treatment of patients with PC... - Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literatureMatthew I Milowsky
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer 94:111-6. 2002..To the authors' knowledge, there are no standard treatment regimens and neither immunotherapy nor chemotherapy have been found to be effective... - Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigenNeil H Bander
Department of Urology, Division of Nuclear Medicine, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 East 68th Street, Starr 900, New York, NY 10021, USA
J Urol 170:1717-21. 2003.... - Chemotherapeutic strategies for renal cell carcinomaMatthew I Milowsky
Division of Hematology/Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, 525 East 68th Street, ST-359, New York, NY 10021, USA
Urol Clin North Am 30:601-9, x. 2003..The identification of novel agents with significantly improved antitumor activity remains a high priority in the treatment of this disease... - Detection of the p110 beta subunit of phosphatidylinositol 3-kinase complexed with neutral endopeptidaseRuoqian Shen
Laboratory of Urological Oncology, Department of Urology, Joan and Sanford I Weill Medical College of Cornell University, 1300 York Avenue, E 300 Box 23, New York, NY 10021, USA
Anticancer Res 22:2533-8. 2002..We previously reported that NEP directly associated with tyrosine-phosphorylated Lyn kinase, and with the p85 subunit of the phosphatidylinositol 3-kinase (PI3 kinase) resulting in an NEP-Lyn-PI3 kinase protein complex... - High expression of the Met receptor in prostate cancer metastasis to boneBeatrice S Knudsen
Department ofPathology, Weill Medical College of Cornell University, New York, New York, USA
Urology 60:1113-7. 2002..CONCLUSIONS: The high expression of the Met receptor tyrosine kinase in bone metastasis renders Met a promising target for nuclear imaging and treatment of metastatic prostate cancer... - Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinomaJonathan S Goldberg
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer 95:1220-7. 2002..ATRA-IV (15 mg/m(2) TIW) and interferon-alpha (3 MU Monday through Friday escalated weekly to 5 MU and to 7 MU) are recommended for further study in patients with advanced RC... - The utility of monoclonal antibodies in the imaging of prostate cancerDaniel Yao
James Buchanan Brady Department of Urology, The New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY 10021, USA
Semin Urol Oncol 20:211-8. 2002..Radioimmunoscintigraphy with this immunoconjugate has demonstrated excellent tumor targeting of prostate cancer sites not only in soft tissue but also in bone... - Estramustine plus a taxane for advanced prostate cancer: the new standard therapy?Matthew I Milowsky
Cancer Invest 20:849-50. 2002 - Synergistic activation of the androgen receptor by bombesin and low-dose androgenJie Dai
Urologic Oncology Research Laboratory, Department of Urology, Joan and Stanford I. Weill Medical College, Cornell University, New York, New York 10021, USA
Clin Cancer Res 8:2399-405. 2002..CONCLUSIONS: These data indicate that bombesin can synergize with low (castrate) levels of DHT to induce AR-mediated transcription and suggest that neuropeptides promote AR-mediated signaling in androgen-independent prostate cancer... - Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigenNeil H Bander
Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
Semin Oncol 30:667-76. 2003..Imaging of patients after they have received radiolabeled J591 demonstrates excellent tumor targeting... - Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigenShankar Vallabhajosula
Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 E 68th Street, STARR 221, New York, NY 10021, USA
J Nucl Med 46:850-8. 2005.... - Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTENMakoto Sumitomo
Urological Oncology Research Laboratory, Department of Urology, Joan and Stanford I Weill Medical College of Cornell University, New York, NY 10021, USA
Cancer Cell 5:67-78. 2004..This study demonstrates a molecular cooperation between NEP and PTEN tumor suppressors in which NEP constitutively recruits and activates PTEN to inhibit the PI3K/Akt oncogenic pathway... - Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimensXiaojia Guo
Department of Pharmacology, Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer Res 62:1654-61. 2002..Collectively, these data implicate aberrant retinoid metabolism in the process of prostatic carcinogenesis... - Antibody-based therapeutics: focus on prostate cancerJeffrey S Ross
Millennium Pharmaceuticals, Inc, Cambridge, MA, USA
Cancer Metastasis Rev 24:521-37. 2005.... 
Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cellsAkio Horiguchi
Urologic Oncology Research Laboratory, Department of Urology, Weill Cornell Medical College of Cornell University, New York, New York, USA
Prostate 68:975-84. 2008..We examined the regulation of merlin expression and merlin phosphorylation in prostate cancer cells...- Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2Oscar B Goodman
Urologic Oncology Research Laboratory, Department of Urology, Weill Medical College of Cornell University New York Presbyterian Hospital, New York, NY, USA
Int J Oncol 31:1199-203. 2007..Thus, although PSMA is a new member of the dual AP and clathrin binding proteins, its alpha-adaptin and clathrin heavy chain binding determinants are distinct from those of other members... - Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data BaseKevin A David
Department of Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York, USA
J Urol 178:451-4. 2007..We reviewed chemotherapy use in patients with stage III transitional cell carcinoma of the bladder from 1998 to 2003 to evaluate perioperative chemotherapy treatment patterns... - Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cellsJin Zhu
Department of Urology, Weill Medical College of Cornell University and New York Presbyterian Hospital, Rm E 300, Box 23, 1300 York Ave, New York, NY 10021, USA
Biochim Biophys Acta 1773:1087-94. 2007.... - Chemosensitization of androgen-independent prostate cancer with neutral endopeptidaseMakoto Sumitomo
Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
Clin Cancer Res 10:260-6. 2004..More importantly, the combination of NEP with anticancer drugs may be a promising therapeutic modality because rNEP is able to augment chemosensitivity in androgen-independent PC with minimal toxicity in normal tissues... - Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteinsAkira Iwase
Urologic Oncology Research Laboratory, Department of Urology, Weill Medical College of Cornell University, New York, New York 10021, USA
J Biol Chem 279:11898-905. 2004..Moreover, cells expressing wild-type NEP demonstrate decreased adhesion to hyaluronic acid and cell migration. These data suggest that NEP can affect cell adhesion and migration through direct binding to ERM proteins... - Of peptides and peptidases: the role of cell surface peptidases in cancerDavid M Nanus
Clin Cancer Res 9:6307-9. 2003 - Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidneyHui Chun Zhan
Pharmacology Department, Weill Medical College, Cornell University, New York, New York 10021, USA
Clin Cancer Res 9:4897-905. 2003..This prompted us to examine the levels of LRAT (lecithin:retinol acyltransferase) protein in various subtypes of human kidney cancers relative to normal human kidney by immunohistochemistry... - Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinomaAkio Horiguchi
Department of Urology, National Defense Medical College, Tokorozawa City, Saitama, Japan
J Urol 176:1631-5. 2006..Because obesity is a significant risk factor for renal cell carcinoma, we investigated the link between leptin and the development of renal cell carcinoma... - Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoterRong Zheng
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, 525 E. 68th Street, ST-359, NY 10021, USA
Mol Cell Endocrinol 259:10-21. 2006.... - Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatmentPeter R Carroll
Department of Urology, University of California School of Medicine, San Francisco 94115-1711, USA
J Urol 170:S3-5. 2003 - Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinomaJay D Raman
Department of Urology, The New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA
Carcinogenesis 27:499-507. 2006..In summary, we were able to detect Rex-1 mRNA and protein expression in over 90% of normal renal parenchymal specimens and we observed a significant reduction in REX1 expression in renal tumor specimens of all histologic subtypes... - Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathwayAkio Horiguchi
Department of Urology, National Defense Medical College, Saitama, Japan
J Urol 176:1636-41. 2006..We examined whether leptin promotes the invasiveness of renal cancer cells and we investigated its underlying signaling pathway...
Research Grants
- NEUTRAL ENDOPEPTIDASE INACTIVATION IN ADVANCED PROSTATEDavid Nanus; Fiscal Year: 2005..abstract_text> ..
- ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIESDavid Nanus; Fiscal Year: 2004..This award will allow Dr. Nanus protected time to successfully complete these aims. ..
- NEUTRAL ENDOPEPTIDASE INACTIVATION IN ADVANCED PROSTATEDavid Nanus; Fiscal Year: 2001..These studies leading to a better understanding of the involvement of NEP in the development and progression of androgen- independent PC may ultimately provide support for novel approaches for the treatment of advanced PC. ..
- Modulation of retinoic acid action in renal cancerDavid Nanus; Fiscal Year: 2005....